OCA
EVMN

Octagon Capital Advisors’s Evommune Inc EVMN Stock Holding History

Octagon Capital Advisors’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.3M Sell
143,472
-356,528
-71% -$8.06M 0.37% 28
2025
Q4 		$8.56M Buy
+500,000
New +$9.39M 1.04% 23

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Octagon Capital Advisors's EVMN Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Evommune Inc (EVMN) stake by 71% in Q1 2026, selling an estimated $8.06M and leaving 143,472 shares worth $3.3M. The position accounts for 0.37% of the portfolio, ranked #28.

Octagon Capital Advisors first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.56M in Q4 2025. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Octagon Capital Advisors held 143,472 shares of Evommune Inc worth $3.3M as of Q1 2026.
  • Octagon Capital Advisors sold 356,528 Evommune Inc shares in Q1 2026, an estimated $8.06M.
  • Evommune Inc made up 0.37% of Octagon Capital Advisors's portfolio in Q1 2026, its #28 holding.
  • Octagon Capital Advisors first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • Octagon Capital Advisors's Evommune Inc position peaked at $8.56M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.